Dymista filed with the FDA

Dymista filed with the FDA

A New Drug Application for a novel formulation of azelastine
hydrochloride and fluticasone propionate, tentatively named “Dymista”,
has been submitted to the U.S. Food and Drug Administration (FDA).
Dymista (also known as MP29-02 in clinical trials), is a nasal spray
formulation for patients 12 years and older with seasonal allergic
rhinitis.

Efficacy and safety of Dymista has been documented in several studies
involving over 4,000 patients, including a long term safety study with
more than 600 patients.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46
709-458 878